Gilead Sciences, Inc. Uses the PHT Corporation LogPad® System for 1st Antianginal Drug to Treat Type 2 Diabetes

  Gilead Sciences, Inc. Uses the PHT Corporation LogPad® System for 1st
  Antianginal Drug to Treat Type 2 Diabetes

World’s most widely used ePRO System leveraged on 14-country, 104-site,
927-patient trial; primary and secondary endpoints achieved, with 98% patient
compliance

Business Wire

BOSTON & GENEVA -- December 2, 2013

The PHT Corporation LogPad^® System was used by Gilead Sciences, Inc. (NASDAQ:
GILD) on the Phase 4 TERISA trial which measured the antianginal effect of
Ranolazine in T2DM patients in the therapeutic areas of cardiology and
endocrinology. PHT Corporation is the leading provider of technologies used to
collect patient-driven eData for clinical research. The LogPad System, which
has been used on more than 650 clinical trials, eliminates data quality
concerns created by a paper diary.

Eight million people in the U.S. alone suffer from chronic stable angina, yet
many patients remain undertreated. Gilead Sciences successfully completed
their TERISA trial and collected the needed FDA regulatory-compliant
patient-reported outcomes (PROs) primary endpoint data with the LogPad System.
The LogPad System was customized to fit the trial’s needs to provide accurate
and verified data.

The result:

  *A clinical trial to support Gilead Sciences’ work to benefit angina
    sufferers
  *Confirmation that eDiaries are an effective and economical way to capture
    angina endpoints such as episodes and dyspnea in angina patients vs.
    treadmill or paper diaries
  *Evidence that global patients, including elderly patients, demonstrate
    high and stable compliance with diary completion at 98%

Download the complete case study here: http://bit.ly/PHTCaseStudies

Patrick Yue MD, Director of Cardiovascular Clinical Research at Gilead
Sciences, explained, “Gilead Sciences chose the PHT LogPad System because it
eliminated poor quality paper diary data and logistics concerns. Observing the
patient-reported number of angina episodes and sublingual nitroglycerin use
over a period of time follows the increasing regulatory emphasis on PROs. It
also provides a significantly more cost-effective trial design. With the PHT
LogPad System, an ePRO diary could be designed and customized to fit the exact
TERISA trial needs.”

Watch Dr. Yue talk about his experience working with PHT on the TERISA trial:
http://bit.ly/GileadVideo

The LogPad System was advantageous vs. other ePRO providers because PHT has
significant experience in the angina indication, having run previous global
Phase 3 angina studies in similar regions around the world. Additionally, PHT
enabled Gilead to integrate data from the LogPad System directly into an
Electronic Data Capture System, Medidata Rave, to streamline data management.
PHT’s international logistics expertise allowed for seamless device delivery,
trial integration and translation into local languages in 14 countries
including Russia.

PHT President and CEO Philip Lee said, “PHT was proud to work with Gilead on
this important study. It is another proof point that PHT eCOA Systems are an
extremely effective method for collecting compliant PROs that enable sponsors
to speed the delivery of new drugs and treatments to patients who need them.”

To hear other case studies, innovations and best practices about PROs and eCOA
Strategy and Systems, register for the 2014 PRO & eCOA Congress at
bit.ly/16EYVSg. PHT invites all Congress alumni to join the exclusive PRO &
eCOA Congress LinkedIn Community to exchange information, ideas and
experiences throughout the year.

About Gilead Sciences, Inc.

Gilead Sciences (NASDAQ: GILD) is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering from
life-threatening diseases worldwide. Headquartered in Foster City, California,
Gilead has operations in North and South America, Europe and Asia Pacific.

About PHT Corporation

PHT Corporation helps pharmaceutical companies and CROs conduct clinical trial
programs with greater confidence, ease and accuracy. Proven PHT electronic
clinical outcome assessment (eCOA) Systems collect patient-driven eData via
smartphones, tablets and the web. This data, available via StudyWorks™ online
reporting portal, provides sponsors and clinicians with a real time window
into how patients feel and function. PHT has helped trial sponsors collect
patient-driven eData in 650+ global trials resulting in 16+ regulatory
approvals. PHT Clinical Science and Consulting offers the scientific,
regulatory, and technological expertise today’s eCOA market demands and
patients deserve. Visit  phtcorp.com for more information on PHT. Follow PHT
on LinkedIn, Twitter, Google+ and YouTube.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20131202005126/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50759297&lang=en

Contact:

For PHT Corporation
Brenda Nashawaty, 617-688-3253
brenda@nashawaty.com